Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

NVX-CoV2373 enters Phase 3 trial for combatting SARS-CoV-2

Staff Writer
Staff Writer 1 year ago
Updated 2021/10/23 at 2:09 PM
Share
SHARE

American biotechnology company Novavax has begun the Phase 3 trial for NVX-CoV2373, the experimental vaccine with the potential to give immunity for combatting SARS-CoV-2 infection in humans. Their new report was released in the New England Journal of Medicine.

“Addressing the unprecedented health crisis of COVID-19 has required extraordinary efforts on the part of government, academia, industry and the community,” said Anthony Stephen Fauci, America’s most trusted physician and the Director of the NIAID, in a news release.

“The launch of this study—the fifth investigational COVID-19 vaccine candidate to be tested in a Phase 3 trial in the United States—demonstrates our resolve to end the pandemic through [sic] development of multiple safe and effective vaccines,” Fauci also stated.

Novavax’s new vaccinational development is expected to be conducted in conjunction with Operation Warp Speed, which aims to expedite the distribution of efficient treatments for counteracting the sudden surge in confirmed cases of COVID-19.

Thus far, NVX-CoV2373 has demonstrated efficiency and was well-tolerated in preceding trials, resulting in higher levels of antibodies to prevent COVID-19 infection. No severe adverse reactions were noted during prior trials.

As Novavax heads to the next phase for their new experimental vaccine, if it demonstrates high efficiency and safeness, it could join the ranks of BNT162b2, Sputnik V, and mRNA-1273, all of which have been strenuously reviewed and approved for immediate distribution.

Novavax is now enrolling adult volunteers in the United States and in Mexico.

Photo: Elliott O'Donovan

You Might Also Like

Study finds vitamin D does not reduce risk of type 2 diabetes

Type 2 diabetes may lead to a significant increase in brain aging and cognitive decline

Study finds no structural brain change during mindfulness-based stress training

Study finds diet may be a contributing factor in ADHD symptoms associated in children

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

TAGGED: COVID-19, epidemiology, SARS-CoV-2
Staff Writer December 28, 2020
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article US population growth slowed significantly from 2019 to 2020
Next Article Elderly people residing in wealthier nations more likely to frequently consume alcohol

Recommended

Clinical

Study finds vitamin D does not reduce risk of type 2 diabetes

2 Min Read
Clinical

Type 2 diabetes may lead to a significant increase in brain aging and cognitive decline

1 Min Read
Clinical

Study finds no structural brain change during mindfulness-based stress training

1 Min Read
Clinical

Study finds diet may be a contributing factor in ADHD symptoms associated in children

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?